Vical Announces News
Release and Conference Call Schedule for 2010 Financial
Results
SAN DIEGO,
Feb. 3, 2011 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced
that the company will report financial results for the three
months and twelve months ended December 31, 2010,
before the opening of trading on
Thursday, February 10, and conduct a conference call and webcast
to discuss the financial results and provide a company
update at noon Eastern Time on
Thursday, February 10. The call is open on a
listen-only basis to any interested parties. The company
will provide details on independent and partnered
development programs in the conference call and webcast.
Conference Call
To listen to the conference call, dial in approximately
ten minutes before the scheduled call to (913) 312-1493
(preferred), or (888) 710-4022 (toll-free), and reference
confirmation code 3159114. A replay of the call will be
available for 48 hours beginning about two hours after the
call. To listen to the replay, dial (719) 457-0820
(preferred) or (888) 203-1112 (toll-free) and enter replay
passcode 3159114. The call also will be available live and
archived through the events page at
www.vical.com.
Invited analysts and institutional investors may ask
questions during the conference call. Others may submit
questions before the call by e-mail addressed to
ir@vical.com or by fax to (858) 646-1150. Submitted
questions will be screened for appropriateness and general
interest. Selected questions received with sufficient notice
before the call will be answered as time permits at the end
of the call. For further information, contact Vical's Investor Relations department by phone at
(858) 646-1127 or by e-mail at
ir@vical.com.
About Vical
Vical
researches and develops biopharmaceutical products based on
its patented DNA delivery technologies for the prevention
and treatment of serious or life-threatening diseases.
Potential applications of the company's DNA delivery
technology include DNA vaccines for infectious diseases or
cancer, in which the expressed protein is an immunogen;
cancer immunotherapeutics, in which the expressed protein is
an immune system stimulant; and cardiovascular therapies, in
which the expressed protein is an angiogenic growth factor.
The company is developing certain infectious disease
vaccines and cancer therapeutics internally. In addition,
the company collaborates with major pharmaceutical companies
and biotechnology companies that give it access to
complementary technologies or greater resources. These
strategic partnerships provide the company with mutually
beneficial opportunities to expand its product pipeline and
address significant unmet medical needs. Additional
information on Vical is available at
www.vical.com.
The Vical
Incorporated
logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=5768
This press release contains forward-looking statements
subject to risks and uncertainties that could cause actual
results to differ materially from those projected.
Forward-looking statements include statements about the
company's focus, collaborative partners, product candidates,
and developmental status. Risks and uncertainties include
whether any product candidates will be shown to be safe and
efficacious in clinical trials, the timing of clinical
trials, whether
Vical or its collaborative partners will seek or gain
approval to market any product candidates, the dependence of
the company on its collaborative partners, and additional
risks set forth in the company's filings with the
Securities and Exchange Commission. These
forward-looking statements represent the company's judgment
as of the date of this release. The company disclaims,
however, any intent or obligation to update these
forward-looking statements.
CONTACT: Alan R. Engbring
(858) 646-1127
Website: www.vical.com
|